Sponsorship verdict
Sponsorship possible
One solid signal, not two. Worth applying, and worth asking about sponsorship early.
-
✓
Employer is on a government sponsor recordThe US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first.
-
?
The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
-
?
No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area.
-
✓
What Astrazeneca Pharmaceuticals Lp paid sponsored hires in similar roles15 certified filings for “Associate Director Oncology Outcomes Research” (Medical Scientists, Except Epidemiologists) in MD: $126k–$185k, median $140k.
-
✓
Confirmed live todayWhen a source last listed this job as open.
Details and sources
- Employer is on a government sponsor record
- The US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. Source: LCA disclosure data (US Department of Labor (OFLC)).
- No salary bar for this route
- H-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Astrazeneca Pharmaceuticals Lp paid sponsored hires in similar roles
- 15 certified filings for “Associate Director Oncology Outcomes Research” (Medical Scientists, Except Epidemiologists) in MD: $126k–$185k, median $140k. Most were filed at wage level II (47%) — 2 lottery entries, ≈31% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence. It is not legal advice and never a guarantee: the employer and the immigration authority decide. Sign in to factor in where you can already work.
About the role
Associate Director, CT Network Capacity Planning
At AstraZeneca's Cell Therapy division, we follow science to explore and innovate. We are working towards treating, preventing, modifying, and even curing some of the world's most complex diseases. Here we have the potential to grow our pipeline and positively impact the lives of billions of patients around the world. We are committed to making a difference and have built our business around our passion for science. Now we are fusing data and technology with the latest scientific innovations to achieve the next wave of breakthroughs.
Position Summary
Cell therapy is redefining what's possible in medicine—delivering living, personalized treatments to patients. Behind every successful therapy is a precisely orchestrated manufacturing network where timing, capacity, and coordination must come together flawlessly.
The Associate Director, Cell Therapy Network S&OE will lead the near-term execution horizon (0–90 days), bridging approved network supply plans with day-to-day operational reality. This role translates network plans and planning guardrails into executable site capacity plans, rolling slot schedules, and cross-functional execution priorities and, critically, orchestrates end-to-end patient order fulfillment across the vein-to-vein journey. The incumbent will own execution against the plan, manage deviations in real time, and drive cross-functional decisions that ultimately determine whether a patient receives their treatment on time.
This role sits at the nerve center of one of the most consequential processes in autologous cell therapy—optimizing slot availability, service levels, and cost across a complex global network. Additionally, this role will lead the scalability of slot management, evolving to an AI and digitally enabled and commercially ready operating model with strong governance, real-time visibility, and rigorous performance management.
Responsibilities
Responsibilities
Cell Therapy Network S&OE Planning & Capacity Optimization
• Lead Cell Therapy internal network capacity planning across the 0–90 day S&OE horizon, including RCCP and detailed 90-day scheduling.
• Translate approved supply plans and demand inputs into executable site-level capacity plans aligned to manufacturing capability, readiness, and constraints, validating execution assumptions and schedule feasibility required to deliver the approved network plan.
• Own the S&OE operating cadence, including the weekly cross-functional S&OE review and the daily execution huddle structure, ensuring disciplined rhythm, clear decision-making, and timely escalation across the network.
• Maintain live visibility of critical network constraints including manufacturing suite availability, QC lab throughput, logistics capacity, and critical raw materials (e.g., viral vector, media) to enable proactive identification and resolution of execution risks.Support trade-off analysis and recovery options within approved guardrails when demand, readiness, or capacity shifts affect execution.
• Partner with stakeholders to identify constraints early and recommend mitigations, including allocation changes, resource needs, ramp plans, and future-state improvements.
• Close the loop with S&OP by feeding recurring execution issues, capacity shortfalls, and demand signal deviations back into tactical and strategic planning cycles, ensuring S&OE insights drive continuous improvement in the broader planning process.
Patient Slot Management
• Operationalize approved slot allocation rules, governance, and recovery processes within the broader capacity planning model.
• Manage slot allocation and recovery in alignment with planning rules, patient readiness, and regulatory, logistics, and manufacturing constrai
Apply on employer site ↗